We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Sets out COVID-19 testing for hospice patients and staff.
Service personnel treated at the Royal Centre for Defence Medicine or the Defence Medical Rehabilitation Centre Headley Court.
How to apply for a clinical trial including eligibility, phases, model IMPDs, costs and how to make changes to your application.
The National Treatment Agency for Substance Misuse (NTA) was established in 2001 to improve the availability, capacity and effectiveness of drug treatment. It became part of Public Health England in 2013.
A new pathway supporting innovative approaches to the safe, timely and efficient development of medicines to improve patient access.
Information on cleaning an oil spill including your options, how to get a product approved and how long it will take.
Explains testing from 1 April 2024 onwards and sets out the purpose of ongoing testing, who will be eligible to access testing and when tests should be used.
Visit the UK for medical treatment - check if you’re eligible and if you need a visa, what visa to apply for, what to do when you travel to the UK.
Overview of the UK's cancer research infrastructure and the advantages of investing in the UK's life science sector to develop new treatments.
Safety leaflet on topical corticosteroids and withdrawal reactions to help patients and their carers to use these medicines safely.
Following its Phase 1 investigation, the CMA has found that Theramex's proposed purchase of Femoston and Duphaston could reduce competition and choice for hormone replacement therapy treatments.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.